L
Leuko Labs
Developing the first device for non-invasive white cell monitoring
About Leuko Labs
Leuko Labs, an MIT spin-out, is a medical technology company that has developed PointCheck™, a non-invasive device for monitoring white blood cell levels. The company targets chemotherapy patients, who are often immunosuppressed and at high risk for infections and febrile neutropenia.
Read full description
The core technology utilizes AI and computer vision for biomedical imaging. The portable, phone-sized device works by shining light through the skin of a patient's finger to count white blood cells as they flow past a miniature lens, eliminating the need for blood draws. This process allows for frequent, at-home monitoring, which can improve clinical outcomes and reduce hospital admissions for cancer patients.
The business model appears to be centered on the sale of this medical device. The company has secured funding, including a $5 million Series A round, to validate the technology and bring it to market. The primary market is healthcare, specifically oncology, serving patients undergoing treatments that affect their immune systems.
At a glance
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Nina Capital
Good Growth Capital
National Institutes of Health
Series A2 investors entered at this stage
IAG Capital Partners
HTH
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Leuko Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Leuko Labs on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.